| PROREPAIR-B: a prospective cohort study of the impact of germline DNA repair mutations on the outcomes of patients with metastatic castration-resistant prostate cancer E Castro, N Romero-Laorden, A Del Pozo, R Lozano, A Medina, J Puente, ... Journal of Clinical Oncology 37 (6), 490-503, 2019 | 319 | 2019 |
| Immune-related adverse events predict the therapeutic efficacy of anti–PD-1 antibodies in cancer patients J Rogado, JM Sánchez-Torres, N Romero-Laorden, AI Ballesteros, ... European Journal of Cancer 109, 21-27, 2019 | 219 | 2019 |
| A mutation in the POT1 gene is responsible for cardiac angiosarcoma in TP53-negative Li–Fraumeni-like families O Calvete, P Martinez, P Garcia-Pavia, C Benitez-Buelga, ... Nature communications 6 (1), 8383, 2015 | 158 | 2015 |
| When should we order a next generation sequencing test in a patient with cancer? R Colomer, R Mondejar, N Romero-Laorden, A Alfranca, ... EClinicalMedicine 25, 2020 | 113 | 2020 |
| Plasma androgen receptor and docetaxel for metastatic castration-resistant prostate cancer V Conteduca, A Jayaram, N Romero-Laorden, D Wetterskog, S Salvi, ... European urology 75 (3), 368-373, 2019 | 78 | 2019 |
| Circulating and disseminated tumor cells in ovarian cancer: a systematic review N Romero-Laorden, D Olmos, T Fehm, J Garcia-Donas, I Diaz-Padilla Gynecologic oncology 133 (3), 632-639, 2014 | 61 | 2014 |
| Inherited mutations in DNA repair genes and cancer risk N Romero-Laorden, E Castro Current problems in cancer 41 (4), 251-264, 2017 | 60 | 2017 |
| Association between BRCA2 alterations and intraductal and cribriform histologies in prostate cancer R Lozano, DC Salles, S Sandhu, IM Aragón, H Thorne, F López-Campos, ... European Journal of Cancer 147, 74-83, 2021 | 46 | 2021 |
| Phase II pilot study of the prednisone to dexamethasone switch in metastatic castration-resistant prostate cancer (mCRPC) patients with limited progression on abiraterone plus … N Romero-Laorden, R Lozano, A Jayaram, F López-Campos, MI Saez, ... British Journal of Cancer 119 (9), 1052-1059, 2018 | 38 | 2018 |
| Plasma AR status and cabazitaxel in heavily treated metastatic castration-resistant prostate cancer V Conteduca, E Castro, D Wetterskog, E Scarpi, A Jayaram, ... European Journal of Cancer 116, 158-168, 2019 | 34 | 2019 |
| Effect of excess weight and immune-related adverse events on the efficacy of cancer immunotherapy with anti-PD-1 antibodies J Rogado, N Romero-Laorden, JM Sanchez-Torres, AM Ramos-Levi, ... Oncoimmunology 9 (1), 1751548, 2020 | 30 | 2020 |
| HSD3B1 (1245A> C) germline variant and clinical outcomes in metastatic castration-resistant prostate cancer patients treated with abiraterone and enzalutamide: results from two … DJ Khalaf, IM Aragón, M Annala, R Lozano, S Taavitsainen, D Lorente, ... Annals of Oncology 31 (9), 1186-1197, 2020 | 26 | 2020 |
| Early post-treatment prostate-specific antigen at 4 weeks and abiraterone and enzalutamide treatment for advanced prostate cancer: an international collaborative analysis P Rescigno, D Dolling, V Conteduca, M Rediti, D Bianchini, C Lolli, M Ong, ... European urology oncology 3 (2), 176-182, 2020 | 22 | 2020 |
| Targeted Sequencing Reveals Low-Frequency Variants in EPHA Genes as Markers of Paclitaxel-Induced Peripheral Neuropathy M Apellániz-Ruiz, H Tejero, L Inglada-Pérez, L Sánchez-Barroso, ... Clinical Cancer Research 23 (5), 1227-1235, 2017 | 20 | 2017 |
| The homologous recombination deficiency scar in advanced cancer: agnostic targeting of damaged DNA repair V Pacheco-Barcia, A Muñoz, E Castro, AI Ballesteros, G Marquina, ... Cancers 14 (12), 2950, 2022 | 15 | 2022 |
| Emotional distress in cancer patients during the first wave of the COVID-19 pandemic P Toquero, C Blanco Fernández, MP López Martí, B Hernández Marín, ... Frontiers in Psychology 12, 755965, 2021 | 15 | 2021 |
| PROREPAIR-B: A prospective cohort study of DNA repair defects in metastatic castration resistant prostate cancer (mCRPC) EC Marcos, NR Laorden, JMP Rodriguez, A del Pozo, MI Sáez, ... Annals of Oncology 28, v619, 2017 | 15 | 2017 |
| Usefulness and real-world outcomes of next generation sequencing testing in patients with cancer: an observational study on the impact of selection based on clinical judgement R Colomer, J Miranda, N Romero-Laorden, J Hornedo, ... EClinicalMedicine 60, 2023 | 14 | 2023 |
| Presence of somatic/germline homologous recombination repair (HRR) mutations and outcomes in metastatic castration-resistant prostate cancer (mCRPC) patients (pts) receiving … D Olmos, D Lorente, D Alameda, C Cattrini, N Romero-Laorden, ... Journal of Clinical Oncology 41 (16_suppl), 5003-5003, 2023 | 12 | 2023 |
| Immunotherapy in advanced prostate cancer: current knowledge and future directions F López-Campos, P Gajate, N Romero-Laorden, J Zafra-Martín, M Juan, ... Biomedicines 10 (3), 537, 2022 | 12 | 2022 |
